AnaptysBio (NASDAQ:ANAB) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of AnaptysBio (NASDAQ:ANAB) from a hold rating to a buy rating in a research note issued to investors on Saturday.

Several other research analysts have also issued reports on the stock. Barclays assumed coverage on shares of AnaptysBio in a research note on Monday, October 13th. They issued an “overweight” rating and a $78.00 target price on the stock. Stifel Nicolaus upped their target price on shares of AnaptysBio from $55.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. UBS Group reiterated a “neutral” rating and issued a $20.00 price objective (up from $18.00) on shares of AnaptysBio in a report on Tuesday, August 12th. JPMorgan Chase & Co. upped their target price on AnaptysBio from $42.00 to $80.00 and gave the stock an “overweight” rating in a report on Thursday, July 24th. Finally, Wedbush boosted their price objective on shares of AnaptysBio from $45.00 to $70.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 15th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, AnaptysBio has a consensus rating of “Moderate Buy” and an average price target of $61.30.

AnaptysBio Stock Up 3.8%

Shares of ANAB opened at $39.65 on Friday. The stock’s 50-day moving average price is $28.81 and its 200 day moving average price is $24.70. The firm has a market capitalization of $1.10 billion, a price-to-earnings ratio of -14.06 and a beta of 0.16. AnaptysBio has a 12-month low of $12.21 and a 12-month high of $40.96.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $1.58. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%.The business had revenue of $76.32 million during the quarter, compared to analysts’ expectations of $15.83 million. Equities research analysts expect that AnaptysBio will post -6.08 EPS for the current year.

Institutional Trading of AnaptysBio

A number of institutional investors and hedge funds have recently made changes to their positions in ANAB. BIT Capital GmbH bought a new stake in shares of AnaptysBio during the 1st quarter worth $473,000. HighMark Wealth Management LLC lifted its holdings in shares of AnaptysBio by 58.2% in the second quarter. HighMark Wealth Management LLC now owns 145,550 shares of the biotechnology company’s stock worth $3,231,000 after acquiring an additional 53,550 shares during the last quarter. Nuveen LLC acquired a new stake in shares of AnaptysBio in the 1st quarter valued at approximately $1,041,000. First Light Asset Management LLC grew its holdings in shares of AnaptysBio by 433.3% during the 1st quarter. First Light Asset Management LLC now owns 4,633,602 shares of the biotechnology company’s stock valued at $86,139,000 after purchasing an additional 3,764,720 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ acquired a new position in AnaptysBio during the 1st quarter worth approximately $623,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.